[1] 国家食品药品监督管理总局.关于药品注册审评审批若干政策的公告[EB/OL]. (2015-11-11)[2016-08-15].http://www.cfda.gov.cn/WS01/CL0087/134665.html. [2] 孙一楠.日本医药产业研究及对我国的启示[D].沈阳药科大学,2003. [3] 俞正威,王珊.日本制药工业的迅速发展及原因探讨[J].药学进展, 1986, (3):1-6. [4] 王勇.日本药品审批独立行政公法人制度[J].中国党政干部论坛,2016, (3):59-61. [5] Pharmaceuticals and Medical Devices Agency. Organization Chart[EB/OL]. (2016-06-21)[2016-08-15].http://www.pmda.go.jp/files/000213106.pdf. [6] 向秋静,叶桦.关于国外开展药品上市后再评价相关制度的分析[J].中国药事, 2016, 30(4):406-410. [7] Zheng Xiaoyuan, Zhang Shixia, Yang Song, et al. The impact of drug administration in USA, Europe and Japan on the reform plan in China[J]. Journal of Chinese Pharmaceutical Sciences, 2014, 23(5):324-329. [8] Pharmaceutical and Medical Device Regulatory Science Society of Japan. Drug Risk Management in Japan[M]. Japan:Jiho, Inc.,2010:75. [9] Matsuda S, Aoki K, Kawamata T, et al. Bias in Spontaneous Reporting of Adverse Drug Reactions in Japan[J].Plos One, 2015, 10(5): e0126413. [10] Takahashi H. The history of adverse drug reactions, relief for these health damage and safety measures in Japan.[J]. Yakushigaku Zasshi, 2009, 44(2):64. [11] 牛剑钊,刘佳,李茂忠,等.日本仿制药品质一致性再评价介绍及对我国的启示[J].中国药事, 2013, 27(4):429-431. [12] Weekly R. The Japan PDMA will require pharmaceutical companies to include risk management plans in all applications, for new drug or biosimilar products[J]. Reactions Weekly, 2012, 1431(1):3. [13] 厚生労働省.医薬品、医療機器等の品質、有効性及び安全性の確保等に関する法律[EB/OL].(2004-09-22)[2016-08-15].http://wwwhourei.mhlw.go.jp/cgi-bin/t_docframe.cgi?MODE=hourei&DMODE=CONTENTS&SMODE=NORMAL&KEYWORD=&EFSNO=651. [14] 沈群红, 张诗情, 崔诗月. 药品不良反应赔偿制度的国际比较与借鉴[J]. 中国卫生政策研究, 2016, 9(9):41-46. [15] 宋春黎,牛剑钊,张启明,等.日本药品再评价制度介绍[J].中国药学杂志,2014, 49(12):1087-1091. [16] 魏水易.药品上市后的再审查和再评价制度[J].药物流行病学杂志, 1999, 8(4):193-196. [17] 郑洁,陈玉文.日本药品品质再评价工程对我国仿制药一致性评价的借鉴[J].中国药业, 2014, (18):6-7. |